Disorders Stocks List

Disorders Stocks Recent News

Date Stock Title
May 14 FULC Fulcrum Therapeutics Inc (FULC) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
May 13 FULC Fulcrum upgraded by Goldman Sachs ahead of Phase 3 data
May 13 FULC Deep Dive Into Fulcrum Therapeutics Stock: Analyst Perspectives (4 Ratings)
May 13 BAX Baxter's Clinolipid gets FDA approval for use in infants
May 13 XGN Exagen, Inc. (XGN) Q1 2024 Earnings Call Transcript
May 13 FULC Sanofi strikes $1bn deal with Fulcrum for muscular dystrophy drug
May 13 FULC Fulcrum Therapeutics, Inc. (FULC) Q1 2024 Earnings Call Transcript
May 13 FULC Sanofi gains license for ex-U.S. rights to Fulcrum muscular dystrophy candidate
May 13 BAX (BAX) - Analyzing Baxter Intl's Short Interest
May 13 XGN Exagen Inc. (XGN) Reports Q1 Loss, Tops Revenue Estimates
May 13 BAX Baxter Secures FDA Approval of Clinolipid (Lipid Injectable Emulsion) Neonatal and Pediatric Indication
May 13 FULC Fulcrum Therapeutics Q1 2024 Earnings: Misses Analyst Net Income Projections Amid Strategic ...
May 13 XGN Exagen beats top-line and bottom-line estimates; raises FY24 outlook
May 13 XGN Exagen Inc. Reports Strong First Quarter 2024 Results: Raises Guidance for Full Year
May 13 FULC Sanofi gambles $80M on Fulcrum’s muscular dystrophy drug
May 13 FULC Fulcrum Therapeutics GAAP EPS of -$0.43 in-line
May 13 CORT 3 High Insider Ownership US Growth Companies With Earnings Growth Up To 70%
May 13 FULC Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024
May 13 FULC Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy
May 13 CORT Pipeline Moves: Phase III completion for Corcept’s relaorilant
Disorders

Disorder may refer to randomness, non-order, or no intelligible pattern. Disorder may also refer to:

Browse All Tags